{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-023261","form_type":"8-K","ticker":"GRCE","cik":"0001444192","company_name":"Grace Therapeutics, Inc.","filed_at":"2025-06-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.315143+00:00","generated_at":"2026-05-18T23:31:15.893935+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Grace Therapeutics reports FY2025 net loss of $9.6M; NDA for GTx-104 on track for June 2025 submission","bullets":["Net loss of $9.6M ($0.79 per share) vs $12.9M ($1.35) in FY2024, decrease driven by change in warrant liabilities.","R&D expenses rose to $9.5M (FY2024: $4.7M) due to the STRIVE-ON Phase 3 trial; cash at $22.1M.","NDA for GTx-104 for aSAH expected to be submitted to FDA by end of June 2025 following positive Type C meeting.","Secured $15M upfront private placement (led by Nantahala Capital, ADAR1 Partners) with potential $15M from warrants.","STRIVE-ON trial met primary endpoint: 19% reduction in clinically significant hypotension vs oral nimodipine (28% vs 35%)."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-023261","json":"https://secwatch.observer/filing/0001140361-25-023261.json","markdown":"https://secwatch.observer/filing/0001140361-25-023261.md","text":"https://secwatch.observer/filing/0001140361-25-023261.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1444192/000114036125023261/0001140361-25-023261-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1444192/000114036125023261/ef20050698_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T23:31:15.893935+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}